» Articles » PMID: 29288545

A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet

Abstract

Objective: Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions.

Methods: This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks.

Results: At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318).

Conclusions: Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.

Citing Articles

"Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society....

Halpern B, Mancini M, van de Sande-Lee S, Miranda P Arch Endocrinol Metab. 2023; 67(4):e230174.

PMID: 37585688 PMC: 10665066. DOI: 10.20945/2359-4292-2023-0174.


5-HT Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators.

Przegalinski E, Witek K, Wydra K, Kotlinska J, Filip M Nutrients. 2023; 15(6).

PMID: 36986191 PMC: 10058696. DOI: 10.3390/nu15061449.


Mindful Eating, General Mindful Awareness, and Acceptance as Predictors of Weight Loss.

Tronieri J, Wadden T, Pearl R, Berkowitz R, Alamuddin N, Chao A Mindfulness (N Y). 2021; 11(12):2818-2827.

PMID: 33777254 PMC: 7990031. DOI: 10.1007/s12671-020-01493-5.


Long-term effects of weight-reducing drugs in people with hypertension.

Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C Cochrane Database Syst Rev. 2021; 1:CD007654.

PMID: 33454957 PMC: 8094237. DOI: 10.1002/14651858.CD007654.pub5.


Associations between causal attributions for obesity and long-term weight loss.

Pearl R, Wadden T, Chao A, Alamuddin N, Berkowitz R, Walsh O Behav Med. 2019; 46(2):87-91.

PMID: 30657439 PMC: 6639144. DOI: 10.1080/08964289.2018.1556202.